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Abstract
Background: The EQ-5D is a reliable tool for measuring Health-Related Quality of Life (HRQoL).
However, concern has been expressed that it may ignore elements of HRQoL, particularly
cognition. In response to this concern, the EQ-5D has been extended with a cognitive dimension
(EQ-5D+C). The aim of this study was to compare the performance of the EQ-5D and the EQ-
5D+C in elderly patients with cognitive impairments by assessing their construct validity and
responsiveness.
Methods: Data from the MEDICIE study (n = 196) were used, in which all questionnaires were
rated by proxies.
Results: Regarding construct validity, we found similar correlations between the EQ-5D and the
Mini Mental State Examination (MMSE) and between the EQ-5D+C and the MMSE. Furthermore,
both the EQ-5D and the EQ-5D+C were responsive to changes in the MMSE, with the EQ-5D
performing slightly better.
Conclusion: We conclude that the EQ-5D performs well for evaluating HRQoL in a population
with cognitive impairments. Based on the results of this explorative study, it does not seem
necessary to adjust the current classification system by adding a cognitive dimension. However, in
order to compare both instruments regarding utility values, it is necessary to develop a new scoring
algorithm for the EQ-5D+C by conducting a general population study. Considering the explorative
nature of this study, it is recommended that more aspects of the validity of both the EQ-5D and
the EQ-5D+C are explored in patients with cognitive impairments using a more tailored study
design.
Background
The increasing number of older adults who are diagnosed
with dementia has far-reaching implications for health
service delivery and expenditures [1]. Economic evalua-
tions are performed more often to assist decision-makers
in setting priorities, especially with regard to resource allo-
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cation [2]. A central component of economic evaluations
in health care is the use of preference-based instruments
(also called value-based instruments) to measure changes
in Health-Related Quality of Life (HRQoL). Preference-
based measures, such as the EQ-5D [3,4], the SF-6D [5]
and the HUI [6], are standardized multi-dimensional
health state classifications [7]. For each of these instru-
ments, health states have been valued using techniques
such as standard gamble (SG) or time trade-off (TTO) [8].
These valuations were used for each instrument to gener-
ate a scoring algorithm of which a single utility score for
each health state can be deduced.
The EQ-5D is commonly used to measure HRQoL and has
been shown to be responsive, internally consistent and
reliable in the normal population and other patient
groups [9,10] as well as in patients with dementia [11,12].
However, concern has been raised that it may ignore ele-
ments of HRQoL of specific relevance to the elderly such
as vision and hearing [1] and in particular cognition
[1,13-17]. It is known that cognitive problems have an
impact on personality, mood, behavior and global func-
tioning [18], which are domains covered by the EQ-5D,
but cognition might also be regarded as a separate dimen-
sion.
In response to the concern that the EQ-5D ignores cogni-
tion, the EQ-5D has been extended with a cognitive
dimension (EQ-5D+C)[15]. In this study of Krabbe et al.
(which was an adapted Dutch replication of the Global
Burden of Disease study commissioned by the World
Bank) [19], valuations (by means of a rating scale) elicited
from EQ-5D+C descriptions were compared empirically
with parallel EQ-5D descriptions in Dutch faculty mem-
bers (i.e. scientific staff members and management mem-
bers of the Department of Public Health, the Department
of Clinical Epidemiology and Biostatics and the Institute
of Social Medicine).
The EQ-5D+C generated different values compared with
the EQ-5D. Whereas the content validity of the EQ-5D
improved by adding cognition, both versions evoked
equally reliable values. Based on these results, the authors
emphasized the importance of considering the inclusion
of a cognitive dimension. Furthermore, the EQ-5D+C was
used to describe the health status of the Dutch population
and to investigate sociodemographic differences [14].
In this study, the content validity also improved through
the addition of the cognitive dimension, while the relia-
bility remained unaltered. It was concluded by the
authors that the EQ-5D+C is an efficient tool for establish-
ing the health status in the community. Another way to
examine if the EQ-5D should contain a cognitive dimen-
sion is to investigate the performance of the EQ-5D and
the EQ-5D+C in a population with cognitive impair-
ments. The aim of this explorative study was to compare
the performance of the EQ-5D and the EQ-5D+C by
assessing their construct validity and responsiveness in
patients aged 55 and older with cognitive impairments.
Methods
Study population and data collection
Data were derived from the MEDICIE (Maastricht Evalua-
tion of a Diagnostic Intervention for Cognitively Impaired
Elderly) study. The MEDICIE study is a randomized con-
trolled trial (RCT) comparing the effects of a multidiscipli-
nary diagnostic observation center for psychogeriatric
patients (DOC-PG) with care as usual on HRQoL, mental
and physical health, and the costs and use of health care
facilities by patients with psychogeriatric problems [20].
The DOC-PG is an outpatient facility, providing multidis-
ciplinary assessment by somatic screening, psychogeriat-
ric assessment, and evaluation of the required levels of
care for the patient and his (her) carer. The main aim of
the DOC-PG is to improve or maintain the HRQoL of
patients.
In the MEDICIE study, a total of 234 patients and their
caregivers agreed to participate and were included
between July 2002 and October 2004. Randomization
occurred at the level of general practices. The experimental
group visited the new diagnostic facility (DOC-PG),
whereas the control group was treated as usual, i.e. the GP
made the diagnosis or referred the patient to a specialist
facility, namely the Maastricht Memory Clinic (MMC) or
the Department of Old Age Psychiatry of the Community
Mental Health Service (RIAGG). Patients were followed
up after 6 months and 12 months.
All outcome measures, except the Mini Mental State
Examination (MMSE), were collected through personal
interviews with the patient's proxy. After initial assess-
ment by the aforementioned health care professionals,
the baseline MMSE scores were gathered from the patient
records. The researchers (C.W. and D.W) were trained to
assess patients using the MMSE at the 6 and 12 month fol-
low-up. When possible, follow-up scores by the profes-
sionals were used. Sociodemographic data of the patients
(gender, age, living arrangements) and proxies (gender,
age, relationship to patient) were collected at baseline.
Diagnosis was established by the multidisciplinary teams
working at the DOC-PG or the MMC/RIAGG respectively,
and was based on the DSM-IV criteria or other regular cri-
teria [21]. In this study, the baseline data and the data at
the six and 12 month follow-up for the entire group were
used since, for the purpose of this paper, it was not neces-
sary to analyze the data of the control group and the
experimental group separately.Health and Quality of Life Outcomes 2007, 5:33 http://www.hqlo.com/content/5/1/33
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Instruments
Mini Mental State Examination (MMSE)
The MMSE is used to detect cognitive impairment, to
assess its severity and to monitor cognitive changes over
time [22]. The MMSE has a maximum score of 30 points,
with different domains being assessed: orientation in
regard to time and place (10 points), registration of three
words (3 points), attention and calculation (5 points),
recall of three words (3 points), language (8 points), and
visual construction (1 point). Scores below 24 are consid-
ered abnormal and this is the cut-off used for dementia.
Scores in the MMSE are often classified into different cat-
egories: 26–30 (normal ageing), 21–25 (mild dementia),
15–20 (moderate dementia), 10–14 (moderately severe
dementia) and 0–9 (severe dementia). The MMSE has
demonstrated validity and reliability in geriatric, psychiat-
ric, neurological and other medical populations [23], also
in the Netherlands [24].
EQ-5D and EQ-5D+C
The EQ-5D is a generic instrument to measure HRQoL.
The instrument was developed and validated in a number
of European countries including the Netherlands
[3,25,26]. The EQ-5D describes health status according to
five dimensions: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Each dimension has
three levels, namely, "no problems", "some problems"
and "severe problems". This yields 243 potential combi-
nations of health states across the five dimensions. Dolan
et al. [27] have presented 42 of these health states to mem-
bers of a representative sample of the UK general popula-
tion, which were valued using the TTO method. Based on
these valuations, utility scores can be deduced by means
of an additive function. These are now widely used in cost-
utility analyses [28]. Utility scores can vary between -0.59
(worst health) and 1.00 (perfect health). Besides the five
dimensions, the EQ-5D consists of a visual analogue scale
(VAS5D) ranging from 0 (worst imaginable health state) to
100 (best imaginable health state).
The EQ-5D+C is an extended version of the EQ-5D that
includes "cognitive functioning" (memory, concentra-
tion, coherence, IQ) as an additional dimension, with a
similar operationalization of three levels (as described
above) [15]. The EQ-5D+C also includes a VAS5D.
In this study, the EQ-5D was administered completely
first, that is the five dimensions followed by the VAS5D.
Subsequently, the proxies were asked to answer the sixth
dimension concerning cognitive functioning, whereupon
the VAS5D was valued a second time (in this study referred
to as the VAS5D+C). Therefore, in this study, the EQ-5D+C
refers to the additional cognitive functioning dimension
and the VAS5D+C.
Data analysis
Construct validity
Construct validity, the extent to which an instrument cor-
relates with other measures which it should be related to
[29], was estimated by studying correlations between the
EQ-5D and the MMSE and between the EQ-5D+C and the
MMSE at baseline and follow-up measures. Although it
was expected that effects of cognitive impairment were
implicitly expressed in the EQ-5D dimensions concerning
self-care, usual activities and anxiety/depression [18,30],
we hypothesized that the correlations between the EQ-
5D+C and the MMSE were strongest.
Responsiveness
In this study, responsiveness was defined as the correla-
tion of the changes in an instrument to changes in other
measures which it should be related to, using an anchor-
based approach [31,32]. We evaluated whether changes in
the EQ-5D and changes in the EQ-5D+C correlated with
changes in the MMSE, the so-called anchor (external
standard). Again, it was hypothesized that the correlations
between the EQ-5D+C and the MMSE were stronger than
the correlations between the EQ-5D and the MMSE.
Statistical analysis
The software used for the analyses was SPSS version 12.0.1
and STATA version 8.2. Background characteristics of the
participants (both the patients and their proxies) were
summarized using descriptive statistics. Response distri-
butions of the instruments (EQ-5D, EQ-5D+C and
MMSE) are given. Missing data of the participants were
imputed using multiple imputation (MI). MI provides a
useful strategy for dealing with data sets with missing val-
ues. Instead of filling in a single value for each missing
value, Rubin's [33] multiple imputation procedure
replaces each missing value with a set of plausible values
(5) that represent the uncertainty about the right value to
impute. This results in statistically valid inferences that
properly reflect the uncertainty due to missing values.
Kolmogorov-Smirnov tests were used to test for normal-
ity. Non-parametric tests for comparisons were selected.
Associations between the instruments were analyzed with
Spearman rank correlations.
Results
Sample characteristics
Table 1 summarizes sample characteristics. Of the 234
patients that were included in the MEDICIE-study, 64.1%
were females. Of the proxies, 66.7% were females and
mostly children (-in-law) or spouses of the patient
(90.2%). In most cases, dementia (present in 70.1% of the
patients) was associated with Alzheimer's disease
(41.5%). Patients whose etiological diagnoses could notHealth and Quality of Life Outcomes 2007, 5:33 http://www.hqlo.com/content/5/1/33
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be determined were assigned to the "other" groups (i.e.
other dementia or other cognitive impairment).
After six months, 16 patients (6.8%) had died and 11
patients (4.7%) and their caregivers had dropped out of
the study. Four patients (1.7%) did not attend the six
month follow-up because of personal reasons. After 12
months another 11 patients (4.7%) had died and two
more patients (0.9%) and their caregivers had dropped
out of the study. The 27 patients (11.5%) who had died
were excluded from the analyses as well as the 11 study
dropouts (4.7%) who completed only 1 measurement.
Missing data of the remaining 196 patients were imputed
using MI. To make sure the imputations did not influence
our results, separate analyses were performed on the 5
imputed datasets. The results were highly comparable
(data not shown). Therefore, the first imputed dataset was
used for analysis.
Responses in the EQ-5D, EQ-5D+C and MMSE
The responses in the EQ-5D and the EQ-5D+C at baseline
and follow-up measurements are summarized in table 2.
At baseline as well as at the 6 month follow-up, most
patients had problems with cognitive functioning, usual
activities and mobility. At the 12 month follow-up, most
patients had problems with cognitive functioning, usual
activities and self-care. The mean VAS5D+C scores were sig-
nificantly lower than the mean VAS5D scores at all meas-
urements (Wilcoxon Signed Ranks Tests, p = 0.000).
The responses in the MMSE at baseline and follow-up
measurements are summarized in table 3. Most patients
had mild to moderate dementia at all measurements.
Construct validity
Table 4 summarizes the results of the correlations
between the MMSE and the EQ-5D and between the
MMSE and the EQ-5D+C. At baseline, significant correla-
tions were found between the MMSE and the utility score,
and more specifically the self-care dimension and the
usual activities dimension, and the VAS5D of the EQ-5D.
Correlations were also found between the MMSE and the
cognitive dimension and the VAS5D+C of the EQ-5D+C. At
the six month follow-up, correlations were found between
the MMSE and the utility score, and more specifically all
five dimensions, and the VAS5D of the EQ-5D. Correla-
tions were also found between the MMSE and the cogni-
tive dimension and the VAS5D+C of the EQ-5D+C. At the
12 month follow-up, correlations were found between the
MMSE and the utility score, and more specifically all
dimensions except for the pain/discomfort dimension,
and the VAS5D of the EQ-5D. Correlations were also found
between the MMSE and the cognitive dimension and the
VAS5D+C of the EQ-5D+C.
Responsiveness
Table 5 summarizes the results of the correlations
between the change scores of the EQ-5D and the EQ-
5D+C and the change scores of the MMSE. In table 6, the
means for the change scores are outlined. Regarding the
difference between the six month measurement and the
baseline measurement, correlations were found between
changes in the utility score, more specifically the self-care
dimension, of the EQ-5D and the change scores of the
MMSE. Correlations were also found between changes in
the cognitive dimension of the EQ-5D+C and change
scores of the MMSE. Regarding the difference between the
12 month measurement and the baseline measurement,
correlations were found between changes in the utility
score, more specifically the mobility dimension, the self-
care dimension and the usual activities dimension, and
the VAS5D of the EQ-5D and the change scores of the
MMSE. Correlations were also found between changes in
the cognitive dimension and the VAS5D+C of the EQ-5D+C
and the change scores of the MMSE.
Discussion
The aim of this explorative study was to compare the per-
formance of the EQ-5D and the EQ-5D+C by assessing
their construct validity and responsiveness in patients
aged 55 and older with cognitive impairments.
Based on our results it can be concluded that the construct
validity of the EQ-5D and the EQ-5D+C is comparable in
our study population, except for the VAS5D. Results
regarding construct validity of the EQ-5D are in line with
the recent findings of Jönssen et al. [17]. Contrary to our
expectations, correlations between the cognitive dimen-
sion and the MMSE were almost similar to the correla-
tions between the self-care and the usual activities
dimensions and the MMSE. The presence of more and
stronger correlations of both the EQ-5D and EQ-5D+C
with the MMSE at the 12 month follow up measurement
was possibly due to the fact that the dispersion of the
scores using these instruments increased with time. Three
studies also showed that cognitive function was positively
related to HRQoL in cardiac rehabilitation patients [34],
in patients with progressive supranuclear palsy [35] and
in patients with hypertension [36]. Another study [37]
failed to find a relationship between HRQoL and cogni-
tion in patients with dementia.
With regard to responsiveness, the EQ-5D performed
slightly better than the EQ-5D+C, which is also in line
with the findings of Jönssen [17]. An important finding,
again contrary to our expectations, is that changes in the
MMSE corresponded better with changes in the self-care
dimension and the usual activities dimension than with
changes in the cognitive dimension.Health and Quality of Life Outcomes 2007, 5:33 http://www.hqlo.com/content/5/1/33
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However, no judgments were made about the strength of
the correlations, which would provide us with a stricter
criterion regarding the performance of the EQ-5D and
EQ-5D+C. In the literature, different classifications were
found [38-41] a clear gold standard being absent. We
therefore ignored the classifications and merely described
our results. However, it is possible to compare our results
with other studies. Our results were in line with correla-
tions between the EQ-5D and clinical measures found in
other studies involving diseases such as progressive supra-
nuclear palsy (PSP) [35], rheumatoid arthritis (RA) [39]
and stroke [42].
The majority of authors [39,41,42] and others) consid-
ered a Spearman's correlation of > 0.50 to be strong, a cor-
relation of 0.30/0.35 – 0.50 to be moderate and a
correlation < 0.30/0.35 to be weak. Using these classifica-
tions in our study, it can be concluded that both versions
performed well with respect to construct validity, as indi-
cated by strong correlations with the MMSE. Regarding
responsiveness, it can be concluded that the EQ-5D per-
formed moderately, whereas the EQ-5D+C did less well as
indicated by weak correlations with the MMSE. When the
more stringent classification of Landis and Koch [38] is
used (i.e. < 0.00 poor; 0.00–0.20 slight; 0.21–0.40 fair;
0.41–0.60 moderate; 0.61–0.80 substantial and 0.81–
1.00 almost perfect), it can be concluded that the EQ-5D
and the EQ-5D+C performed moderately with regard to
the construct validity.
Regarding responsiveness, fair correlations were found
between changes in the EQ-5D and EQ-5D+C and
changes in the MMSE. The relatively low responsiveness
of the EQ-5D in this study could be due to the, on average,
small changes in cognition in a year, or to a ceiling effect
because there are only three levels for each dimension of
the EQ-5D. Patients' health may improve or decline but
not enough to go up or down one level. Instruments that
have a greater number of possible responses may be more
responsive. Furthermore, it is possible that adaptation to
illness on the part of the proxy leads to a lack of respon-
siveness, especially with a chronic condition such as
dementia [39]. It should also be noted that a lack of clarity
exists with regard to the definition and adequate approach
for evaluating responsiveness. Some authors argued that
there is no need for an additional concept like responsive-
ness, since it can be viewed as either longitudinal validity
or magnitude of the treatment effect [32,43,44]. The defi-
nition and approach used in this study has also been
referred to as longitudinal validity [32].
There are several limitations to this study that need to be
recognized. An important limitation of this study con-
cerns our study design. The origin of this study, the
MEDICIE trial, was designed to compare the effects of a
multidisciplinary diagnostic observation centre for psy-
chogeriatric patients (DOC-PG) with care as usual on
HRQoL, mental and physical health, and the costs and use
of health care facilities by patients with psychogeriatric
Table 1: Sample characteristics at baseline
Total n = 234
Gender of patient:
Female (%) 150 (64.1%)
Age of patient:
Mean (SD) 77.8 (6.7)
Range [55–94]
Relationship proxy:
Spouse 88 (37.6%)
Child (-in-law) 123 (52.6%)
Other 23 (9.8%)
Gender of proxy:
Female (%) 156 (66.7%)
Age of proxy:
Mean (SD) 59.8 (13.9)
Range [30–91]
MMSE:
Mean (SD) 20.18 (5.8)
Dementia: 164 (70.1%)
Alzheimer's Disease (AD) 97 (41.5%)
Vascular Dementia (VD) 26 (11.1%)
Mixed Dementia 21 (9.0%)
Other Dementia 20 (8.5%)
No Dementia: 70 (29.9%)
Cognitive Impairment/MCI 40 (17.1%)
Other Cognitive Impairment 30 (12.8%)Health and Quality of Life Outcomes 2007, 5:33 http://www.hqlo.com/content/5/1/33
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problems. Therefore, studying the usefulness of the EQ-
5D+C in this patient population was framed in this RCT.
The EQ-5D was administered first, that is the five dimen-
sions followed by the VAS5D. Subsequently, the proxies
were asked to answer the sixth dimension concerning cog-
nitive functioning, whereupon the VAS5D+C was valued. It
would have been better to administer the EQ-5D+C com-
pletely as well in order to make valid comparisons
between the 2 versions. However, considering the explor-
ative nature of this study, we did not want to burden the
participants of the MEDICIE trial by administering a sim-
ilar questionnaire twice.
Second, regarding the assessment of the EQ-5D+C, the
proxies may have focused their attention on the cognitive
dimension when scoring the VAS5D+C, even though they
had been instructed to rate the VAS5D+C again based on the
overall health. This effect is called a framing effect, which
suggests that how something is presented (the 'frame')
influences the choices people make [45]. Hence, it is pos-
Table 2: Responses in the EQ-5D and EQ-5D+C (items, utility scores and VAS scores)
EQ-5D N = 196 Baseline 6 months 12 months
Mobility:
Mean (SD) 1.65 (0.48) 1.65 (0.51) 1.67 (0.51)
% no problems 24.7% 36.7% 34.7%
% some problems 65.3% 61.7% 63.3%
% severe problems 0% 1.5% 2.0%
Self-Care:
Mean (SD) 1.59 (0.65) 1.71 (0.73) 1.97 (0.80)
% no problems 50.0% 45.4% 33.2%
% some problems 40.8% 38.3% 36.7%
% severe problems 9.2% 16.3% 30.1%
Usual Activities:
Mean (SD) 1.92 (0.72) 2.02 (0.75) 2.17 (0.78)
% no problems 29.6% 27.0% 23.0%
% some problems 48.5% 44.4% 36.7%
% severe problems 21.9% 28.6% 40.3%
Pain/Discomfort:
Mean (SD) 1.59 (0.65) 1.51 (0.60) 1.54 (0.62)
% no problems 49.5% 54.1% 53.1%
% some problems 41.8% 40.8% 40.3%
% severe problems 8.7% 5.1% 6.6%
Anxiety/Depression:
Mean (SD) 1.66 (0.67) 1.53 (0.59) 1.54 (0.68)
% no problems 44.9% 52.6% 56.6%
% some problems 43.9% 42.3% 33.2%
% severe problems 11.2% 5.1% 10.2%
Utility score:
Mean (SD) 0.54 (0.31) 0.57 (0.32) 0.47 (0.34)
Range -0.35 – 1.00 -0.35 – 1.00 -0.43 – 1.00
VAS5D:
Mean (SD) 58.84 (19.00) 57.78 (17.67) 56.38 (20.29)
Range 10–100 20–100 10–100
EQ-5D+C
Cognition:
Mean (SD) 2.30 (0.58) 2.35 (0.64) 2.47 (0.61)
% no problems 6.1% 8.7% 6.1%
% some problems 58.2% 47.4% 40.8%
% severe problems 35.7% 43.9% 53.1%
VAS5D+C:
Mean (SD) 49.45 (19.23) 48.43 (18.06) 45.41 (18.90)
Range 0 – 100 10 – 90 0 – 95Health and Quality of Life Outcomes 2007, 5:33 http://www.hqlo.com/content/5/1/33
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sible that the higher correlations of the VAS5D+C with the
MMSE are due to a framing effect. However, according to
Parkin et al. [46], the framing bias also exists when assess-
ing the EQ-5D, meaning that values of the VAS5D are
affected by end-state descriptors (last named dimen-
sions).
Another possible limitation is the use of proxies to com-
plete the questionnaires. Previous research indicated that
there is generally fairly good proxy-patient agreement for
observable items such as mobility, self care and usual
activities, but poor agreement for non-observable items
such as pain and affect [16]. Others have found agreement
to be poor for the domains most affected by dementia
(self-care and usual activities) [17]. In the light of the lon-
gitudinal nature of our study, the complex health prob-
lems of our study population and their progressive global
deterioration of intellect and personality, the method of
proxy rating had been chosen. It is generally acknowl-
edged that in the later stages of dementia proxy measures
are required since patients are no longer capable of mak-
ing an adequate evaluation of their HRQoL [12,17]. Fur-
thermore, the use of proxy reports throughout the course
of a longitudinal study, rather than substituting them only
when the person with dementia becomes unable to report
his or her HRQoL, reduces bias over time [47]. The overall
picture of previous research is that rating by proxy is a
valid alternative for assessing HRQoL in the presence of
dementia [17,47-49], although it is possible that the
scores in the EQ-5D and the EQ-5D+C were biased
because of perceived caregiver burden [50].
A final limitation also concerns the design of our study.
Comparisons between the EQ-5D and the EQ-5D+C were
merely based on the dimensions and VAS-scores of both
versions and not on the utility scores since these are not
available for the EQ-5D+C. It should be noted that an
algorithm has been developed for EQ-5D+C health states,
based on Dutch disability weights [51,52]. In the Dutch
disability weights study, a comprehensive set of disease-
specific disability weights for 175 disease stages associated
with 52 disease categories was obtained [53,54]. Based on
these disability weights, an EQ-5D+C regression model
was fitted. However, the origins of the EQ-5D+C disability
weights and the EQ-5D utility scores differ significantly.
First, the algorithm is based on valuations of health
Table 3: Responses in the MMSE
N = 196 Baseline 6 months 12 months
MMSE
Mean (SD) 20.21 (5.78) 18.89 (7.34) 17.61 (8.16)
Severity of dementia:
26 – 30 (normal ageing) 18.4% 21.9% 21.9%
21 – 25 (mild) 35.7% 26.0% 19.4%
15 – 20 (moderate) 29.6% 25.0% 25.0%
10 – 14 (moderately severe) 10.2% 14.3% 15.3%
0 – 9 (severe) 6.1% 12.8% 18.4%
Table 4: Spearman correlations between the EQ-5D and the MMSE and between the EQ-5D+C and the MMSE at baseline, six months 
and 12 months (construct validity)
N = 196 Baseline 6 months 12 months
EQ-5D:
Utility score 0.19** 0.45** 0.50**
Mobility -0.02 -0.17* -0.23**
Self-Care -0.28** -0.50** -0.55**
Usual activities -0.34** -0.42** -0.52**
Pain/Discomfort -0.01 -0.14* -0.05
Anxiety/Depression -0.05 -0.17* -0.22**
VAS5D 0.22** 0.23** 0.23**
EQ-5D+C:
Cognition -0.35** -0.52** -0.54**
VAS5D+C 0.37** 0.47** 0.48**
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)Health and Quality of Life Outcomes 2007, 5:33 http://www.hqlo.com/content/5/1/33
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experts instead of valuations of the general public. Sec-
ond, EQ-5D+C health states were valued by means of the
person trade-off (PTO) method, whereas EQ-5D health
states were valued by means of the time trade-off (TTO)
method [27]. PTO differs from TTO in that subjects are
required to trade-off person years lived healthy against
person years lived with some defined disability, thus mak-
ing choices in the context of a decision involving other
people rather than themselves. Whether the PTO tech-
nique is able to reflect actual preferences is still under
debate [55,56]. Finally, besides the EQ-5D+C health state
description, subjects were given specific information with
respect to the disease, which differs from the EQ-5D valu-
ation procedure [27]. Therefore, in our opinion, no valid
comparison of EQ-5D+C disability weights with EQ-5D
utility scores can be made. In order to develop a new scor-
ing algorithm of which utility scores for the EQ-5D+C can
be deduced, a valuation procedure similar to the one used
for the EQ-5D should be applied. Presenting EQ-5D+C
health states to members of the general population
should reduce the framing effect described earlier, as the
cognitive dimension will then be 'just' one of the six
dimensions in the health states. Furthermore, although in
the descriptive part of the EQ-5D a proxy effect may still
be present, by using a utility score based on valuations of
the general population, possible proxy effects are expected
to decrease.
Conclusion
In this explorative study, the construct validity and
responsiveness of the EQ-5D and the EQ-5D+C were
assessed and compared in patients aged 55 and older with
Table 5: Spearman correlations between the change scores of the EQ-5D and the MMSE, and between the EQ-5D+C and the MMSE, 
i.e. change score of baseline and six months and baseline and 12 months (longitudinal)
Change scores N = 196 Baseline & 6 months Baseline & 12 months
EQ-5D:
Utility score 0.16* 0.30**
Mobility -0.11 -0.17*
Self-Care -0.18* -0.35**
Usual activities -0.12 -0.29**
Pain/Discomfort -0.04 0.03
Anxiety/Depression 0.00 -0.12
VAS5D 0.01 0.17*
EQ-5D+C:
Cognition -0.21** -0.28**
VAS5D+C 0.08 0.23**
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
Table 6: Means of the change scores of the EQ-5D, the EQ-5D+C and the MMSE
Change scores N = 196 Baseline & 6 months Mean (SD) Baseline & 12 months Mean (SD)
EQ-5D:
Utility score 0.02 (0.29) -0.07 (0.31)
Mobility -0.01 (0.44) 0.02 (0.53)
Self-Care 0.12 (0.58) 0.38 (0.71)
Usual activities 0.09 (0.70) 0.25 (0.69)
Pain/Discomfort -0.08 (0.58) -0.06 (0.67)
Anxiety/Depression -0.14 (0.66) -0.13 (0.74)
VAS5D -1.06 (18.00) -2.46 (21.40)
EQ-5D+C:
Cognition 0.06 (0.63) 0.17 (0.66)
VAS5D+C -1.02 (18.36) -4.05 (21.33)
MMSE:
Mean (SD) -1.32 (4.58) -2.61 (5.17)Health and Quality of Life Outcomes 2007, 5:33 http://www.hqlo.com/content/5/1/33
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cognitive impairments. We conclude that the EQ-5D per-
forms well for evaluating HRQoL in our population with
cognitive impairments using proxy ratings. Therefore,
based on the results of this study and given its (serious)
limitations, it does not seem necessary to adjust the cur-
rent classification system by adding a cognitive dimen-
sion. However, in the absence of a gold standard for
measuring HRQoL, a general population study to obtain
valuations for the EQ-5D+C health states could provide a
better insight into whether cognition has a separate and
significant effect on utility values, and would enable us to
compare the utility values deduced from both versions in
a correct manner.
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